Related Experiment Video
Updated: May 20, 2025

An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
Validity of the Updated Rx-Risk Index as a Disease Identification and Risk-Adjustment Tool for Use in Observational
Imaina Widagdo1, Mhairi Kerr1, Lisa Kalisch Ellett1
1Quality Use of Medicines and Pharmacy Research Centre, Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.
Purpose:
Identifying patient health conditions in observational studies is essential for accurately measuring healthcare practices and planning effective health policy interventions. This analysis evaluates the validity of the Rx-Risk Index, a tool that uses medication dispensing data to identify patient comorbidities and measure overall health. We examined an updated version of the Rx-Risk Index, reflecting changes in treatment practices, to assess its validity as a tool for identifying specific health conditions and as a measure of overall health to aid in risk adjustment in observational studies.
Patients And Methods:
We conducted a validation study using two Australian linked health datasets, the Person-Level Integrated Data Asset (PLIDA) and the National Health Data Hub (NHDH), from 2010 to 2018, focusing on individuals aged 65 years or older. The sensitivity, specificity, PPV/NPV, Cohen's kappa, and F1 scores were used to assess agreement between Rx-Risk Index conditions and two reference standards: patient self-reported conditions and hospital diagnosis. The Rx-Risk Index's predictive validity for one-year mortality was also evaluated using logistic regression, with model fit assessed by AIC and c-statistic.
Results:
Data were analysed from 3,959 individuals in PLIDA and 157,709 individuals in NHDH. The Rx-Risk Index showed high sensitivity (≥75%) for diabetes, chronic airways disease, hyperlipidemia, and epilepsy against both self-reported conditions and hospital diagnoses. However, hyperlipidemia and hypertension showed lower specificity (<70%). High PPVs (≥78%) were observed for diabetes and renal failure. The agreement between the Rx-Risk Index and self-reported conditions was stronger (Cohen's kappa: 0.41-0.81 for 7 conditions) than between Rx-Risk Index and ICD10-AM diagnoses (kappa: 0.73 for one condition). The Rx-Risk Index was a strong predictor of one-year mortality, with c-statistic of 0.820 (95% CI: 0.817-0.825).
Conclusion:
Selected Rx-Risk Index conditions are reasonable proxies for identifying specific conditions, particularly those requiring pharmacological management. The Rx-Risk Index was a strong predictor of one-year mortality, suggesting it is a valid measure of overall health. This study demonstrates the Rx-Risk Index's potential to enhance disease classification and risk adjustment in observational studies, supporting informed decision-making in health policy planning.
More Related Videos
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
07:31Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
Published on: May 15, 2020
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Relative Risk
Odds Ratio
Hazard Ratio
For example, in a clinical trial...
The Mantel-Cox Log-Rank Test
Comparing the Survival Analysis of Two or More Groups